Njira Zatsopano Zochizira Matenda Otupa

Morningside Ventures lero yalengeza kukhazikitsidwa kwa Adiso Therapeutics, kampani yazachipatala ya biotechnology yomwe ikupititsa patsogolo njira zatsopano zochiritsira zomwe zikulimbana ndi matenda otupa. Morningside wapereka ndalama za mapulani achitukuko a Adiso mpaka pano, ndikukonzekera kupititsa patsogolo kukula kwa kampaniyo kupita patsogolo.     

Adiso akupita patsogolo ndi njira yatsopano ya mamolekyu ang'onoang'ono omwe ali ndi njira zatsopano zogwirira ntchito komanso mankhwala osokoneza bongo amtundu umodzi (SS-LBP), kutsata zizindikiro za ulcerative colitis (UC), ndi C. difficile matenda (CDI). Kuphatikiza pa mapulogalamu awiri a Phase 1 (UC & CDI) ndi pulogalamu ya Phase 2 (UC), Adiso akupanga pulogalamu yatsopano ya inflammasome mu gawo lodziwikiratu lomwe likufufuzidwa poyambirira mu kutupa kwa kupuma, ndi malo angapo ochiritsira omwe angathe mtsogolo kuti atsatire.

Kampaniyo ili ndi antchito 25 omwe m'mbuyomu, pansi pa ambulera ya Morningside, adatsegula bwino Investigational New Drug (INDs) ndipo adapereka ma patent angapo komanso kupeza US FDA Fast Track Designation, zomwe zidapangitsa kuti Adiso apangidwe. Adiso adzagwira ntchito motsogozedwa ndi Chief Executive Officer, Scott Megaffin. Bambo Megaffin ali ndi zaka zoposa 30 zamakampani komanso mbiri yabwino pa maudindo akuluakulu a utsogoleri ku Bristol-Myers Squibb, Pfizer, Schering-Plough, Adolor, Onconova, ndi Churchill. Posachedwapa, Bambo Megaffin adatumikira monga CEO wa Adastra Pharmaceuticals, kampani ya chitukuko cha oncology, komwe adatsogolera kampaniyo kuchita bwino ndi Cothera Bioscience mu October 2021.  

"Zofunikira zachipatala zomwe sizinakwaniritsidwe zilipo pazithandizo zatsopano zomwe zimayang'ana kuyambika kwa matenda otupa osayambitsa chitetezo chamthupi," atero a Jason Dinges, Morningside Technology Advisory ndi Adiso Board Member. "Adiso akutuluka pachipata ndi mapulogalamu atatu odalirika kwambiri ochiza matenda am'mimba komanso kupewa CDI yobwerezabwereza. Tikukhulupirira kuti motsogozedwa ndi Scott komanso gulu laluso la akatswiri opanga mankhwala osokoneza bongo, Adiso ali wokonzeka kuchita bwino.

"Ku Adiso tikulimbana ndi matenda otupa pogwiritsa ntchito njira zosiyanasiyana komanso molimba mtima. Tikuwona chowonadi chatsopano kwa odwala, kutengera kupita patsogolo kwamankhwala otupa omwe akulonjeza kukonzanso chitetezo cha mthupi la wolandirayo, kuti matenda oyambitsa matendawo asapitirire komanso kuti wodwalayo asakhale ndi chitetezo chamthupi, "atero a Scott Megaffin, CEO wa Adiso Therapeutics. . "Ndili ndi mwayi kutsogolera gulu lapadera, lapamwamba padziko lonse lapansi, komanso lodzipereka ku Adiso pakupanga mankhwala apaderawa omwe amapangidwa kuti athetse vuto lomwe limabwera chifukwa cha kutupa."

Mustafa A. Noor, MD, FACP walowanso gulu la utsogoleri wa Adiso. Dr. Noor akutenga udindo wa Chief Medical Officer, akubweretsa zaka zoposa 20 za luso lachitukuko cha mankhwala m'madera ambiri ochiritsira m'makampani angapo oyambirira mpaka apakatikati ndi apadziko lonse kuphatikizapo AMAG Pharmaceuticals, Akcea Therapeutics, Ipsen, Pfizer, Glaxo-Smith Kline. , ndi Bristol Myers Squibb.

"Kutupa kwapang'onopang'ono kumakhala pakati pa matenda ambiri oopsa ndipo kuwonongeka komwe kumayambitsa kumawononga thanzi ndi thanzi la odwala. Njira zamakono zochizira ndizosakwanira kuletsa kukula kwa matenda ndikusintha moyo wabwino m'njira yotetezeka komanso watanthauzo, "adatero Dr. Noor, CMO wa Adiso Therapeutics. "Makhalidwe apadera a Adiso portfolio pochiza matenda otupa amatha kukhala mankhwala ofunikira kwa odwala. Kutengera maphunziro opambana azachipatala komanso oyambilira mpaka pano, ndikuyembekeza kutsogolera magawo otsatirawa azachipatala pazachipatala chathu ndi gulu lodziwa bwino lomwe la akatswiri azachipatala. ”